한글목차

본 보고서는 주요 8개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본, 중국)의 천식 및 중증 천식에 대해 조사 분석하여 위험인자 및 동반질환, 과거 역학 동향에 대한 정보를 제공합니다.

목차

제1장 천식 및 중증 천식 : 주요 요약

• 촉매
• 관련 보고서
• 향후 보고서

제2장 역학

• 질환 배경
• 위험인자와 병존질환
• 세계의 과거 동향
• 주요 8개 시장 예측 방법
• 천식 및 중증 천식 역학 예측(2023-33년)
  • 12개월 이내에 진단된 천식 환자 수
  • 12개월 이내에 진단된 천식 환자 수 : 연령별
  • 12개월 이내에 진단된 천식 환자 수 : 성별
  • 생애에 진단된 천식 환자 수
  • 생애에 진단된 천식 환자 수 : 연령별
  • 생애에 진단된 천식 환자 수 : 성별
  • 12개월 이내에 진단된 중증 천식 환자 수
  • 12개월 이내에 진단된 중증 천식 환자 수 : 연령별
  • 12개월 이내에 진단된 중증 천식 환자 수 : 성별
  • 생애에 진단된 중증 천식 환자 수
  • 생애에 진단된 중증 천식 환자 수 : 연령별
  • 생애에 진단된 중증 천식 환자 수 : 성별
  • 12개월 이내에 진단된 중증 천식 환자 수 : 염증 아류형별
  • 생애에 진단된 중증 천식 환자 수 : 염증 아류형별
• 논의
  • 역학 예측 인사이트
  • COVID-19의 영향
  • 분석의 한계
  • 분석의 강점

제3장 부록

영문목차

Asthma is a common lung condition that is characterized by the narrowing and swelling of the airways of the lungs and the production of excess mucus (Mayo Clinic, 2024). Common symptoms of asthma include wheezing, breathlessness, chest tightness, and coughing at night or early in the morning (NHS, 2021; CDC, 2024). These symptoms may come and go for some people, but severe episodes of symptoms, or asthma attacks, can be life-threatening (Mayo Clinic, 2024). Asthma symptoms can be managed with regular medication (Mayo Clinic, 2024). Asthma can affect people of all ages, but usually develops in childhood. Sometimes, asthma can develop for the first time in adulthood (NHS, 2021). In 2018, the global burden of asthma was estimated to affect 339 million people. Globally, asthma is the 16th most common cause of years lived with disability (Global Asthma Network, 2022).

Severe asthma, as defined by the Global Initiative for Asthma (GINA), is a subset of difficult-to-treat asthma that remains uncontrolled despite adherence to maximum optimal high-dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) treatment and management of contributory factors, or that worsens when high-dose treatment is decreased (Global Initiative for Asthma, 2023). The European Respiratory Society (ERS) and American Thoracic Society (ATS) have also defined severe asthma, although it is functionally the same as the GINA definition used for this report (Chung et al., 2014). Severe asthma is categorized into type 2 inflammation, which includes eosinophilic and allergic asthma, and non-type-2 inflammation, which includes neutrophilic asthma (American Lung Association, 2024). Treatments for these types of asthma differ. The GINA estimates that the worldwide prevalence of severe asthma among asthma patients is around 3.7%, based on a study from the Netherlands (Global Initiative for Asthma, 2023).

Scope

• The Asthma and Severe Asthma Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of asthma and severe asthma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
• The report includes a 10-year epidemiological forecast for the 12-month and lifetime diagnosed prevalent cases of asthma and severe asthma, segmented by age (0 years up to 80 years older by 10-year age groups) and sex. The 12-month and lifetime diagnosed prevalent cases of severe asthma are further segmented by inflammatory subtype (atopic or allergic asthma, eosinophilic or neutrophilic).

Reasons to Buy

• The Asthma and Severe Asthma Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global asthma and severe asthma markets.
• Quantify patient populations in the global asthma and severe asthma markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for asthma and severe asthma therapeutics in each of the markets covered.
• Understand magnitude of the asthma and severe asthma population by age and sex and the severe asthma population by inflammatory subtype.

Table of Contents

Table of Contents

• About GlobalData

1 Asthma and Severe Asthma: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities.
• 2.3 Global and historical trends
• 2.4 8MM forecast methodology.
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods.
  • 2.4.3 Forecast assumptions and methods: 12-month diagnosed prevalent cases of asthma - 8MM.
  • 2.4.4 Forecast assumptions and methods: lifetime diagnosed prevalent cases of asthma - 8MM.
  • 2.4.5 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma.
  • 2.4.6 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma.
  • 2.4.7 Forecast assumptions and methods: 12-month diagnosed prevalent cases of severe asthma by inflammatory subtypes.
  • 2.4.8 Forecast assumptions and methods: lifetime diagnosed prevalent cases of severe asthma by inflammatory subtypes.
• 2.5 Epidemiological forecast for asthma and severe asthma (2023-33)
  • 2.5.1 12-month diagnosed prevalent cases of asthma
  • 2.5.2 Age-specific 12-month diagnosed prevalent cases of asthma.
  • 2.5.3 Sex-specific 12-month diagnosed prevalent cases of asthma
  • 2.5.4 Lifetime diagnosed prevalent cases of asthma
  • 2.5.5 Age-specific lifetime diagnosed prevalent cases of asthma.
  • 2.5.6 Sex-specific lifetime diagnosed prevalent cases of asthma
  • 2.5.7 12-month diagnosed prevalent cases of severe asthma
  • 2.5.8 Age-specific 12-month diagnosed prevalent cases of severe asthma
  • 2.5.9 Sex-specific 12-month diagnosed prevalent cases of severe asthma
  • 2.5.10 Lifetime diagnosed prevalent cases of severe asthma
  • 2.5.11 Age-specific lifetime diagnosed prevalent cases of severe asthma
  • 2.5.12 Sex-specific lifetime diagnosed prevalent cases of severe asthma
  • 2.5.13 12-month diagnosed prevalence of severe asthma by inflammatory subtypes
  • 2.5.14 Lifetime diagnosed prevalence of severe asthma by inflammatory subtypes
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 Primary research - high prescriber survey
• 3.3 About the Authors
  • 3.3.1 Epidemiologist
  • 3.3.2 Reviewers
  • 3.3.3 Vice President of Disease Analysis and Intelligence
  • 3.3.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us